Moderna Stock Price, News & Analysis

Moderna, Inc. (NASDAQ:MRNA) has announced a new supply agreement with the Colombian government to deliver 10.8 million doses of its COVID-19 vaccine. This follows a previous supply of 10 million doses in 2021. Deliveries are scheduled for 2022, with one million doses in Q1, six million in Q2, and 3.8 million in Q3. Additionally, Moderna has signed a supply agreement with Chile for two million booster doses, pending emergency use authorization. The vaccine, SPIKEVAX, has received emergency use authorization from Colombia’s Invima.

Moderna, Inc. (NASDAQ:MRNA) will hold a live conference call and webcast on February 24, 2022, at 8:00 a.m. ET to discuss its fourth quarter and full year 2021 financial results.

Investors can join the call by dialing 866-922-5184 (domestic) or 409-937-8950 (international), using conference ID 5682797. A webcast will be accessible on the Moderna investor website and archived for one year post-call. Moderna continues to advance its mRNA platform to develop vaccines and therapeutics across various diseases, marking a decade of innovation and partnerships in the biopharmaceutical sector.

Moderna's Spikevax COVID-19 vaccine has received full approval from the U.S. FDA for individuals aged 18 and older. This marks a significant achievement as Spikevax is the company's first product to gain full licensure in the U.S., complementing its existing approvals in over 70 countries, including Canada and the EU. The decision was based on extensive safety and efficacy data, affirming Spikevax's role in combating the pandemic. In 2021, 807 million doses were shipped worldwide, with a significant portion supplied to low- and middle-income countries.

IAVI and Moderna have initiated a Phase 1 clinical trial for an experimental HIV vaccine at George Washington University. The trial aims to evaluate mRNA-based immunogens' ability to induce neutralizing antibodies in healthy participants. Following promising results from a previous trial, this study will examine the effectiveness of the mRNA platform in vaccine design. The trial involves 56 volunteers and aims to produce critical immune responses against HIV variants. Supported by the Bill & Melinda Gates Foundation, this research represents a significant step in HIV vaccine development.

Moderna has commenced the Phase 2 study of its Omicron-specific booster candidate, mRNA-1273.529, with the first participant dosed. The study aims to evaluate the immunogenicity and safety of the booster in two cohorts: those with a primary series of mRNA-1273 and those with an additional 50 µg booster dose. While neutralizing antibodies against Omicron showed a 6.3-fold decline six months post-boost, they remained detectable in all participants. Moderna plans to share findings to inform public health decisions on booster strategies against SARS-CoV-2.

Moderna (NASDAQ:MRNA) reported shipping 807 million doses of its COVID-19 vaccine globally in 2021, with approximately 25% delivered to low- and middle-income countries. The company achieved product sales of about $17.5 billion for the year and has secured advanced purchase agreements (APAs) for 2022 totaling around $18.5 billion. Moderna is expanding its mRNA pipeline with 40 programs, including ongoing studies for COVID-19 and flu vaccines, and has partnered with Carisma Therapeutics for cancer therapy developments. The company remains focused on reinvesting in R&D and expanding its manufacturing capabilities.

On January 10, 2022, Moderna (NASDAQ: MRNA) announced a strategic collaboration with Carisma Therapeutics to develop in vivo engineered chimeric antigen receptor monocyte (CAR-M) therapeutics for cancer treatment. The agreement includes a $45 million upfront cash payment and a $35 million convertible note from Moderna to Carisma. Carisma will handle discovery, while Moderna will lead clinical development and commercialization. This partnership aims to enhance Moderna's oncology pipeline and leverage both companies' expertise in mRNA and engineered macrophages.

Moderna has initiated a Phase 1 study for its mRNA-1189 vaccine targeting Epstein-Barr Virus (EBV), with the first participant dosed. The trial, named Eclipse, aims to enroll approximately 270 participants in the U.S. EBV can cause infectious mononucleosis, with significant health impacts and no current vaccine available. The study will assess the safety and tolerability of mRNA-1189 in adults aged 18-30. Moderna is developing vaccines against latent viruses, expanding its portfolio alongside its CMV vaccine candidate.

Moderna, Inc. (NASDAQ:MRNA) will have its CEO, Stéphane Bancel, participate in a fireside chat at the Goldman Sachs 14th Annual Healthcare CEOs Unscripted Conference on January 6th, 2022, at 2:00 p.m. ET. A live webcast will be accessible in the Investors section of Moderna's website, with a replay available for 30 days post-event. Moderna has evolved over the past decade from an mRNA research-stage company to a leader in mRNA therapeutics and vaccines, contributing significantly to COVID-19 vaccine development.